Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Jeil Pharmaceutical is a leading South Korean pharmaceutical company focused on the development and commercialization of innovative therapies across various therapeutic areas, including oncology, neurology, and gastroenterology. The company is well-known for its robust R&D pipeline, featuring candidates like JPI-547, a dual PARP and Tankyrase inhibitor for solid tumors, and JPI-289 for acute ischemic stroke. Jeil operates both as a traditional pharmaceutical manufacturer with a wide range of generic and licensed products and as a biotech innovator through its subsidiary, Onconic Therapeutics. The company maintains significant manufacturing capabilities and strategic partnerships with global pharmaceutical firms to bring advanced healthcare solutions to the Korean and international markets.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on JPI Pharmaceutical.